What Happened?
Shares of biotech company Regeneron (NASDAQ: REGN) jumped 2.9% in the afternoon session after the company announced an expanded cancer therapy collaboration and reported positive clinical trial data for one of its treatments.
Regeneron is broadening its research partnership with CytomX Therapeutics to create new cancer therapies. As part of the expanded agreement, Regeneron will pay CytomX $37 million to nominate two additional drug targets. The total value of the collaboration could reach approximately $4 billion in potential milestone payments, and CytomX would also receive royalties on sales.
Separately, Regeneron presented encouraging data from a Phase I/II trial of its drug, Lynozyfic, for treating light-chain amyloidosis, a rare disease. The results showed a 100% complete response rate in patients who received a 240mg dose. These positive developments in the company's drug pipeline appear to be driving investor optimism.
After the initial pop, the shares cooled down to $619.97, up 2.8% from the previous close.
Is now the time to buy Regeneron? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Regeneron’s shares are not very volatile and have only had 4 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The previous big move we wrote about was 16 days ago when the stock dropped 10.5% on the news that its experimental cancer treatment failed to meet the main goal in a late-stage study for patients with a type of advanced skin cancer.
The company announced its Phase 3 trial for a combination of its drugs, fianlimab and cemiplimab, did not achieve statistical significance in improving progression-free survival—the time patients live without their disease worsening.
Although the trial showed a numeric improvement, the results were not definitive enough to be considered a success, raising investor concerns about the drug's future. The study compared the treatment against Merck & Co.'s established drug, Keytruda, for patients with advanced melanoma. Adding to the negative sentiment, Citi downgraded Regeneron's stock to Neutral from Buy and significantly lowered its price target, citing the "disappointing" trial data.
Regeneron is down 20.1% since the beginning of the year, and at $619.97 per share, it is trading 23.7% below its 52-week high of $812.27 from January 2026. Despite the year-to-date decline, investors who bought $1,000 worth of Regeneron’s shares 5 years ago would now be looking at an investment worth $1,226.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
